Please login to the form below

Not currently logged in
Email:
Password:

evobrutinib

This page shows the latest evobrutinib news and features for those working in and with pharma, biotech and healthcare.

Merck takes evobrutinib for MS into phase 3, on mixed data

Merck takes evobrutinib for MS into phase 3, on mixed data

Merck KGaA is putting its BTK inhibitor evobrutinib to the test in two phase 3  multiple sclerosis (MS) trials, the first drug in the class to reach that stage for the ... The new trials – dubbed EVOLUTION RMS 1 and 2 – will compare twice-daily oral

Latest news

  • New data backs Merck’s segue into MS with BTK inhibitor New data backs Merck’s segue into MS with BTK inhibitor

    Patients had fewer lesions on evobrutinib than placebo. BTK inhibitors are already establishing themselves as important new drugs in cancer, but Merck KGaA has the first data suggesting they could also ... That mechanism also forms the basis of Merck’s

  • Lilly drops Hanmi-partnered arthritis drug Lilly drops Hanmi-partnered arthritis drug

    Merck KGaA is among the front-runners among companies developing BTK inhibitors for inflammatory diseases, with its evobrutinib progressing to phase IIb testing in rheumatoid arthritis last September, while Bristol-Myers

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...